Profusa Seeks to Acquire G3 Vision Labs in Potential Deal
Profusa has entered an option agreement that could allow it to acquire diagnostics-focused company G3 Vision Labs, along with its subsidiaries. The deal is conditional on several factors including shareholder approval and raising at least $30 million in financing. If completed, the acquisition would significantly expand Profusa’s diagnostic offerings by adding laboratory tests for infectious diseases, toxicology screening, autoimmune services, and tissue analysis. G3 Vision Labs reported estimated 2025 revenue of around $111 million and operates primarily in pain management, behavioral health, and addiction treatment. The combined entity is expected to function as a public diagnostics company. However, the market has reacted negatively; Profusa's stock dropped nearly 9% before trading on August 3. The deal aligns with growing interest in precision medicine and diagnostic innovation within healthcare.
Tickers: $PFSA
Topics: diagnostics digital_health healthcare